Advertisement

Drugs

pp 1–12 | Cite as

Migalastat: A Review in Fabry Disease

  • Emma H. McCaffertyEmail author
  • Lesley J. Scott
Adis Drug Evaluation
  • 62 Downloads

Abstract

Fabry disease is a rare lysosomal disorder characterized by deficient or absent α-galactosidase A activity resulting from mutations in the GLA gene. Migalastat (Galafold™), a pharmacological chaperone, stabilizes and facilitates trafficking of amenable mutant forms of α-galactosidase A enzyme from the endoplasmic reticulum to lysosomes and increases its lysosomal activity. Oral migalastat is the first pharmacological chaperone approved for treating patients [aged ≥ 18 years (USA and Canada) or ≥ 16 years in other countries] with Fabry disease who have a migalastat-amenable GLA mutation. In the FACETS trial in enzyme replacement therapy (ERT)-naive patients with GLA mutations amenable or non-amenable to migalastat, there was no significant difference between the migalastat and placebo groups for the proportion of patients achieving a ≥ 50% reduction in the number of globotriaosylceramide (GL-3) inclusions/kidney interstitial capillary (KIC) at 6 months [primary endpoint; intent-to-treat (ITT) population]. In the modified ITT population (i.e. patients with migalastat-amenable GLA mutations), relative to placebo, migalastat treatment significantly reduced the mean number of GL-3 inclusions/KIC and plasma lyso-globotriaosylsphingosine levels at 6 months. Among evaluable patients, migalastat maintained renal function and reduced cardiac mass after ≤ 24 months’ therapy. In the ATTRACT trial in ERT-experienced patients, renal function was maintained during 18 months of migalastat or ERT; however, migalastat significantly reduced cardiac mass compared with ERT. Migalastat was generally well tolerated in both of these trials. Given its convenient oral regimen and the limited therapeutic options available, migalastat is an important treatment option for Fabry disease in patients with migalastat-amenable GLA mutations.

Notes

Acknowledgements

During the peer review process, the manufacturer of migalastat was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Emma McCafferty and Lesley Scott are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–27.CrossRefGoogle Scholar
  2. 2.
    Amicus Therapeutics. Galafold™ (migalastat) capsules, for oral use: US prescribing information. 2018. https://www.fda.gov/. Accessed 18 Oct 2018.
  3. 3.
    European Medicines Agency. Migalastat (Galafold): EU summary of product characteristics. 2018. https://www.ema.europa.eu/. Accessed 18 Oct 2018.
  4. 4.
    Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163–7.CrossRefGoogle Scholar
  5. 5.
    National Institute for Health and Care Excellence. Migalastat for treating Fabry disease. 2017. https://www.nice.org.uk/guidance/hst4. Accessed 26 Oct 2018.
  6. 6.
    Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631–41.CrossRefGoogle Scholar
  7. 7.
    Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis. 2001;24(7):715–24.CrossRefGoogle Scholar
  8. 8.
    Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson–Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40(9):1668–74.CrossRefGoogle Scholar
  9. 9.
    Hauth L, Kerstens J, Yperzeele L, et al. Galactosidase alpha p.A143T variant of Fabry disease may result in a phenotype with multifocal microvascular cerebral involvement at a young age. Front Neurol. 2018;9:336.CrossRefGoogle Scholar
  10. 10.
    Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.CrossRefGoogle Scholar
  11. 11.
    Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003;13(4):305–13.CrossRefGoogle Scholar
  12. 12.
    Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease—a comprehensive review of the medical literature. Genet Med. 2010;12(11):668–79.CrossRefGoogle Scholar
  13. 13.
    Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91(2):284–93.CrossRefGoogle Scholar
  14. 14.
    Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23(7):1138–48.CrossRefGoogle Scholar
  15. 15.
    Benjamin ER, Flanagan JJ, Schilling A, et al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis. 2009;32(3):424–40.CrossRefGoogle Scholar
  16. 16.
    Fan J-Q, Ishii S, Asano N, et al. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5(1):112–5.CrossRefGoogle Scholar
  17. 17.
    Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. Faseb J. 2005;19(1):12–8.CrossRefGoogle Scholar
  18. 18.
    Asano N, Ishii S, Kizu H, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000;267(13):4179–86.CrossRefGoogle Scholar
  19. 19.
    Yam GH, Bosshard N, Zuber C, et al. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol. 2006;290(4):C1076–82.CrossRefGoogle Scholar
  20. 20.
    Khanna R, Soska R, Lun Y, et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther. 2010;18(1):23–33.CrossRefGoogle Scholar
  21. 21.
    Ishii S, Chang H-H, Yoshioka H, et al. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J Pharmacol Exp Ther. 2009;328(3):723–31.CrossRefGoogle Scholar
  22. 22.
    Young-Gqamana B, Brignol N, Chang HH, et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS ONE. 2013;8(3):e57631.CrossRefGoogle Scholar
  23. 23.
    Johnson FK, Mudd PN Jr, Bragat A, et al. Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers. Clin Pharmacol Drug Dev. 2013;2(2):120–32.CrossRefGoogle Scholar
  24. 24.
    Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012;7(91):1–11.Google Scholar
  25. 25.
    Giugliani R, Waldek S, Germain DP, et al. A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013;109(1):86–92.CrossRefGoogle Scholar
  26. 26.
    Tuttolomondo A, Simonetta I, Duro G, et al. Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson–Fabry disease. OncoTarget. 2017;8(37):61415–24.CrossRefGoogle Scholar
  27. 27.
    Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288–96.CrossRefGoogle Scholar
  28. 28.
    Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430–8.CrossRefGoogle Scholar
  29. 29.
    Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545–55.CrossRefGoogle Scholar
  30. 30.
    Wu X, Katz E, Della Valle MC, et al. A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat. 2011;32(8):965–77.CrossRefGoogle Scholar
  31. 31.
    Johnson FK, Mudd PN Jr, DiMino T, et al. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function. Clin Pharmacol Drug Dev. 2015;4(4):256–61.CrossRefGoogle Scholar
  32. 32.
    Ino H, Takahashi N, Terao T, et al. Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects. J Drug Assess. 2013;2(1):87–93.CrossRefGoogle Scholar
  33. 33.
    Johnson FK, Valenzano KJ, Castelli JP, et al. Pharmacokinetic simulation of a 150 mg QOD dose regimen for the pharmacological chaperone migalastat HCl in Fabry disease [abstract no. 001]. Clin Pharmacol Drug Dev. 2017;6(Suppl. 1):3.Google Scholar
  34. 34.
    Johnson FK, Mudd PN Jr, Janmohamed SG. Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(3):193–202.CrossRefGoogle Scholar
  35. 35.
    Mudd PN, Johnson FK, Churchill A. A phase 1 study to investigate the absorption, metabolism and excretion of [14C] migalastat hydrochloride following a single oral administration in healthy volunteers [abstract no. 1699358]. Clin Pharmacol Drug Dev. 2013;2(Suppl. 1):18–9.Google Scholar
  36. 36.
    Amicus Therapeutics. NDA multi-disciplinary review and evaluation: Galafold (migalastat). 2017. https://www.fda.gov/. Accessed 6 Nov 2018.
  37. 37.
    Mauer M, Sokolovskiy A, Barth JA, et al. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet. 2017;54(11):781–6.CrossRefGoogle Scholar
  38. 38.
    Schiffmann R, Bichet DG, Jovanovic A, et al. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13(68):1–7.Google Scholar
  39. 39.
    The Renal Association. CKD stages G1 or G2. 2018. https://renal.org/information-resources/the-uk-eckd-guide/stages-1-2-ckd/. Accessed 19 Dec 2018.
  40. 40.
    National Kidney Foundation. Glomerular filtration rate (GFR). 2017. https://www.kidney.org/atoz/content/gfr. Accessed 19 Dec 2018.
  41. 41.
    Torra R, Germain D, Bichet D, et al. Clinical outcomes with migalastat in patients with Fabry disease based on degree of renal impairment: results from phase 3 trials [abstract no. SP002 and poster]. Nephrol Dial Transplant. 2018;33(Suppl. 1):i346.CrossRefGoogle Scholar
  42. 42.
    Germain DP, Giugliani R, Bichet DG, et al. Efficacy of migalastat in a cohort of male patients with the classic Fabry phenotype in the FACETS phase 3 study [abstract no. 102]. Mol Genet Metab. 2017;120(1–2):S52.Google Scholar
  43. 43.
    Schiffmann R, Bichet D, Germain D, et al. Effects of long-term migalastat treatment on renal function by baseline proteinuria in patients (PTS) with Fabry disease [abstract no. SP004 and poster]. Nephrol Dial Transplant. 2018;33(Suppl. 1):i346–7.Google Scholar
  44. 44.
    Jovanovic A, Schiffmann R, Nicholls K, et al. Improvements in cardiac mass with long-term migalastat treatment in patients with Fabry disease: results from phase 3 trials [abstract no. LBN 02]. J Inborn Errors Metab Screen. 2017;5:1–2.Google Scholar
  45. 45.
    Muentze J, Gensler D, Salinger T, et al. Treatment of cardiac manifestations in Fabry disease with the oral drug migalastat: first 12 months results from a cohort of amenable all-comers [abstract no. 2355]. Eur Heart J. 2018;39(Suppl. 1):460.Google Scholar
  46. 46.
    Health Canada. Galafold™ (migalastat) capsules: Canadian product monograph. 2017. https://pdf.hres.ca/dpd_pm/00041104.PDF. Accessed 16 Jan 2019.
  47. 47.
    Japanese Pharmaceuticals and Medical Devices Agency. Galafold capsule 123 mg: Japanese prescribing information. 2018. http://www.info.pmda.go.jp/go/pack/3999045M1028_1_01/. Accessed 18 Oct 2018.
  48. 48.
    Therapeutic Goods Administration. Galafold® (migalastat): Australian product information. 2018. https://www.tga.gov.au/sites/default/files/auspar-migalastat-180830-pi.pdf. Accessed 16 Jan 2019.
  49. 49.
    Mauer M, Glynn E, Svarstad E, et al. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS ONE. 2014;9(11):e112188.CrossRefGoogle Scholar
  50. 50.
    Lenders M, Weidemann F, Kurschat C, et al. Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11(1):54.CrossRefGoogle Scholar
  51. 51.
    Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in Fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101–8.CrossRefGoogle Scholar
  52. 52.
    Germain DP, Brand E, Burlina A, et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med. 2018;6(4):492–503.CrossRefGoogle Scholar
  53. 53.
    Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med. 2009;1(5):268–79.CrossRefGoogle Scholar
  54. 54.
    European Medicines Agency. Agalsidase beta (Fabrazyme): EU summary of product characteristics. 2018. https://www.ema.europa.eu/. Accessed 26 Oct 2018.
  55. 55.
    European Medicines Agency. Agalsidase alfa (Replagal): EU summary of product characteristics. 2018. https://www.ema.europa.eu/. Accessed 26 Oct 2018.
  56. 56.
    Mohamed FE, Al-Gazali L, Al-Jasmi F, et al. Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises. Front Pharmacol. 2017;8:448.CrossRefGoogle Scholar
  57. 57.
    Therapeutic Goods Administration. Australian public assessment report for migalastat. 2018. https://www.tga.gov.au/sites/default/files/auspar-migalastat-180830.pdf. Accessed 16 Jan 2019.
  58. 58.
    Sirrs S, Bichet DG, Iwanochko RM, et al. 2017 Canadian Fabry disease guidelines. 2017. http://www.garrod.ca/wp-content/uploads/Canadian-FD-Treatment-Guidelines-2017.pdf. Accessed 16 Jan 2019.
  59. 59.
    US National Institutes of Health. ClinicalTrials.gov identifier NCT03683966. 2018. https://clinicaltrials.gov/. Accessed 16 Jan 2019.
  60. 60.
    BlueCross BlueShield of Arizona. Galafold™ (migalastat) oral capsule: pharmacy coverage guidelines. 2018. https://www.azblue.com/~/media/azblue/files/pharmacy-forms-mastery-directory/qualified-health-plans/pharmacy-coverage-guidelines-and-precertification-forms/galafold.pdf. Accessed 17 Jan 2019.
  61. 61.
    Amicus Therapeutics. Galafold™ (migalastat) capsules: NDA approval letter. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208623Orig1s000ltr.pdf. Accessed 18 Dec 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations